telaglenastat + palbociclib

**Telaglenastat + palbociclib** is a combination therapy composed of *telaglenastat*, a selective, oral inhibitor of human glutaminase (CB-839), and *palbociclib*, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Telaglenastat blocks glutamine consumption by tumor cells, targeting a critical metabolic dependence often caused by genetic alterations, such as KRAS mutations, while palbociclib inhibits CDK4/6-driven cell cycle progression. The rationale for combination treatment is preclinical evidence for synergistic anti-tumor activity, notably in cancers with KRAS and/or CDKN2A mutations, enhancing cell cycle arrest and blocking proliferation. This combination is being investigated in phase 1/2 trials for advanced/metastatic KRAS-mutated colorectal cancer, KRAS-mutated non-small cell lung cancer, and pancreatic ductal adenocarcinoma with KRAS and CDKN2A mutations[1][3][5][7]. Telaglenastat was developed by Calithera Biosciences; palbociclib was developed and is manufactured by Pfizer.

Brand names

Ibrance + telaglenastat

Other names

telaglenastatpalbociclib